Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

University of Campania "Luigi Vanvitelli"

Status and phase: Completed; Phase 1

Conditions: Myopia

Treatments: Drug: Combination therapy "IVB + rf-PDT"

Study type: Interventional

Funder types: Other

Identifiers

NCT00802126

81613

Details and patient eligibility

About

The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.

Full description

In this retrospective interventional case series, 16 patients with myopic CNV were included. All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later. All patients were previously treated with IVB monotherapy and active leaking of CNV occurred 90 to 120 days after the treatment.

Best-corrected visual acuity (BCVA-ETDRS), foveal thickness (FT) on optical coherence tomography (OCT), and fluorescein and indocyanine green angiographic (FA; ICG) findings were recorded. Follow-up evaluations were carried out for 12 months.

Enrollment: 16 patients

Sex: All

Ages: 35 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Myopic CNV, CNV leakage

Exclusion criteria

• CNV not associated with high myopia
• No activity of CNV

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

Bevacizumab and verteporfin

Experimental group

Treatment:

Drug: Combination therapy "IVB + rf-PDT"